. Author manuscript; available in PMC: 2016 Nov 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2015 Jul 14;21(11):1948–1954. doi: 10.1016/j.bbmt.2015.07.005

Table 3B.

Correlation of day +90 to +120 T-lymphocyte chimerism with three-year cumulative incidence of chronic GVHD

	T-lymphocyte chimerism ≤ 85%	T-lymphocyte chimerism > 85%
	% 3-year cumulative incidence^* (95% CI)	% 3-year cumulative incidence^* (95% CI)	HR	95% CI	P
cGVHD overall	52% (41-63)	59% (53-66)	0.8	0.6-1.2	0.4
cGVHD in CR1/CR2	58% (45-74)	61% (53-71)	0.94	0.6-1.5	0.8
cGVHD in non-CR1/CR2	37% (20-66)	56% (46-68)	0.6	0.2-1.4	0.2

Accounting for disease progression or death before cGVHD as competing risks